APPENDIX 1: PRISMA-P Checklist

APPENDIX 2: Search strategy

APPENDIX 3: Extraction Form (please, find the Excel document in the first submission)

APPENDIX 4: Financial Conflicts of Interest Forms

Section and topic	Item	Checklist item	Reported on page	
		ADMINISTRATIVE INFORMATION		
Title: Identification	1a	Identify the report as a protocol of a systematic review.	(Page 1, title page)	
Update	Update 1b If the protocol is for an update of a previous systematic review, identify as such.		(N/A)	
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number.	(Page 4)	
Authors:				
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author.	(Page 1, title page)	
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review.	(Page 11)	
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments.	(N/A)	
Support: Sources Sponsor	5a 5b	Indicate sources of financial or other support for the review. Provide name for the review funder and/or sponsor.	(Page 11) (Page 11)	
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol.	(Page 11)	
		INTRODUCTION		
Rationale	6	Describe the rationale for the review in the context of what is already known.	(Pages 3 and 4)	
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO).	(Page 4)	
		METHODS		
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review.	(Page 5)	
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage.	(Page 6)	
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated.	(Page 6)	
Study records:				
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review.	(Page 6)	
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis).	(Page 7)	
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators.	(Page 7)	

Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications.	(Pages 7 and 8)
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale.	(Pages 7 and 8)
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis.	(Pages 8)
	15a	Describe criteria under which study data will be quantitatively synthesised.	(Pages 8 and 9)
Data synthesis	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of	(Page 9)
2	15c	consistency (such as I ² , Kendall's τ). Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression).	(Page 9)
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	(Page 8)
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies).	(Page 9)
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE).	(Page 10)

Search strategy

Set	Purpose	Search strategy Search
1	Anthropometry	weight OR body size OR height OR BMI OR body mass index OR overweight OR obesity OR waist circumference OR waist-hip ratio OR fat mass OR body fat OR lean tissue OR lean mass OR skin folds OR skin fold OR skinfold
2	Diet	diet OR feeding OR nutrition OR food intake OR dietary intake OR feeding behavior OR food OR drink OR beverages OR "Diet, Food, and Nutrition"[Mesh]
3	Other Lifestyle Components	physical activity OR physical inactivity OR sedentary lifestyle OR smoking OR alcohol OR alcohol drinking OR alcoholism
4	Blood Pressure	blood pressure OR hypertension OR cardiovascular diseases OR cardiovascular
5	Lipid Profile	lipidic profile OR lipid profile OR triglycerides OR hypertriglyceridemia OR cholesterol OR total cholesterol OR LDL OR HDL OR hypercholesterolemia
6	Glucose Metabolism	glucose OR hemoglobin glycated OR HbA1c OR glucose metabolism disorders OR glycemia OR hyperglycemia OR insulin OR diabetes OR insulin resistance OR HOMA OR homeostatic model assessment OR metabolic syndrome OR syndrome X
7	Iron Status	iron OR ferritin OR hemoglobin OR anemia OR hepcidin OR TIBC OR transferrin
8	Inflammation and Cytokines	inflammation OR C Reactive Protein OR CRP OR Interleukin OR IL1 OR IL-1 OR IL2 OR IL-2 OR IL6 OR IL-6 OR IL8 OR IL-8 OR IL12 OR IL-12 OR IL16 OR IL-16 OR Tumor Necrosis Factor- alpha OR TNF-alpha OR TNFα OR retinol-binding protein 4 OR RBP4 OR adipokines OR adiponectin OR leptin OR resistin
9	Lifestyle and Cardio- metabolic Profile	OR 1-8
10	Mapuche Population	Mapuche OR Pehuenche OR Araucanian OR Chilean native OR Argentine native OR Chilean ethnicity OR Argentine ethnicity OR Chilean aboriginal OR Argentine aboriginal OR Chilean indigenous OR Argentine indigenous OR Chilean Amerindian OR Argentine Amerindian OR Chilean indians OR Argentine indians OR "Indians, South American"[Mesh]
11	Lifestyle, Cardio- metabolic Profile and Mapuche Population	AND 9-10
12	Human Limit	animals
13	Final Result	NOT 11-12

Table 1: Financial Conflicts of Interest Checklist 2010

(Underlined terms are defined in the Glossary)

The Financial Conflicts of Interest Checklist 2010 was designed to be completed by each investigator in the context of a specific clinical research study.

As awareness of financial conflict of interest issues grows, we see the checklist being completed by other study team members, such as study coordinators, research assistants and study nurses. This checklist contains four sections: administrative information, study information, personal financial information, and authorship information. The investigator is expected to complete the checklist prospectively as the clinical research moves through its various stages. Sections 1, 2 and 3 are first filled out at the study's initiation, updated as required, and completed when the study manuscript is submitted for publication; section 4 is also completed at this time.

SECTION 1: ADMINISTRATIVE INFORMATION

This section is completed at the study's initiation and updated as necessary.

TEM	DESCRIPTOR		RESPONS	E
A.1.0	Study	Role of ethnicity and environment on lifestyle an population: A protocol for systematic review and		
A.1.1	Study name			
A.1.2	Singlesite or	multi-site		
A.1.3	Countries in whic	h the data will be collected	Chile	
A.1.4	Is this a <u>clinical tr</u>	ial?	🔲 Yes	No
A.1.4a	If you answere	ed yes to item A.1.4:		
	international	gistered in a primary <u>clinical trial registry</u> that follows tandards developed by the World Health Organization and he International Committee of Medical Journal Editors?	Yes	🗋 No 📄 Don't know
		red registries can be found at ho.int/ictrp/network/primary/en/index.html		
A.1.4b	What is the pr	imary registry name and the registration number?		
A.1.5	Name of the inst	itution from which the study will be coordinated	Atacama	University
A.1.6	Is any part of the	study to be conducted by a <u>contract research organization</u> ?	🔲 Yes	No
A.2.0	Investigator			
A.2.1	Name of the <u>ove</u>	rall study official	José C. Fe	rnández Cao
A.2.2	Name of the inve	estigator completing the checklist	José C. Fe	rnández Cao
A.2.3	What is your role	in this research study? (check all that apply)		
A.2.3a	Principal inves	tigator for the entire study	Yes	🔲 No
A.2.3b	Principal inves	tigator for a site or region	🔲 Yes	No
А.2.3с	Co-investigato	or for the study	🔲 Yes	No
A.2.3d	Paid consultar	nt for the study	🔲 Yes	No
А.2.3е	Member of st	eering committee	🔲 Yes	No
A.2.3f	Participant ree	cruiter	🔲 Yes	No
A.2.3g	Other (please	specify)		
Date the cl	necklist section 1 wo	is first completed (day/month/year)	19/10/20	18

Date(s) the checklist section 1 was updated (day/month/year)

SECTION 2: STUDY INFORMATION

This section is completed at the study's initiation and updated as necessary.

MODULE B: FUNDER PROFILE				
ITEM	DESCRIPTOR	RESPONSE		
B.1.0	Is this studyfunded?	Yes 🗋 No 🗋 Don't know		
B.1.1	If you answered yes to item B.1.0, identify the type of funding support:			
	📕 Financial 🔲 Equipment 🔲 Test kit 🔲 Drug 🔲 Device	The principal investigator (JCFC) is		
B.1.2	Other (please specify:) List the funder(s)	supported by the Project ATA1756 of the Ministry of Education of Chile.		
B.1.3	To which categories do/does the funder(s) belong? (check all that apply):			
В.1.3а	Industry (e.g., pharmaceutical company, test or medical device company, biotech company)	🗋 Yes 📕 No		
B.1.3b	Government funding agency (e.g., National Institutes of Health, Canadian Institutes of Health Research, Medical Research Council)	Yes No		
В.1.3с	National or regional government body (e.g., National Health Service, Ministry of Health, Department of Defense)	Yes 🗋 No		
B.1.3d	Charitable foundation (e.g., American Heart Association, The Bill & Melinda Gates Foundation, Wellcome Trust)	🗋 Yes 📕 No		
B.1.3e	Other(s) (please specify:)	🗋 Yes 📕 No		

MODULE	C: CONTRACT PROFILE	
ITEM	DESCRIPTOR	RESPONSE
C.1.0	Is there a <u>contract</u> with the funder(s)? (If you answered no or don't know, skip to module D) If you answered yes to item C.1.0, does your contract:	🗋 Yes 📕 No 🗋 Don't know
C.1.1	include someone signing on behalf of your institution?	🗋 Yes 🔲 No
C.1.2	require you to obtain additional funds for this research study from other sources?	Yes No
C.1.3	contain a clause that prohibits you from disclosing certain aspects about the study without the permission of the funder?	🗋 Yes 🔲 No
C.1.4	specify the maximum allowable time for pre-publication review by the funder?	Yes No
С.1.4а	If you answered yes to item C.1.4, what is that time?	days

	: STUDY TEAM AND FUNDER RELATIONSHIP	PROFILE			
ITEM	DESCRIPTOR		RESPON	SE	
D.1.0	Who bears final responsibility for and/or has u authority over the following areas of the stuc				
D.1.1	Conceptualizing and designing the study *+	Study team	🔲 Funder	Shared§	Don't know
D.1.2	Approving the final design ⁺	Study team	🔲 Funder	Shared§	🔲 Don't know
D.1.3	Approving the final data analysis plan	Study team	🔲 Funder	Shared§	Don't know
D.1.4	Recruiting participants	Study team	🔲 Funder	Shared§	🔲 Don't know
D.1.5	Collecting or assembling data*+	Study team	🔲 Funder	Shared§	Don't know
D.1.6	Analyzing the data*†	Study team	🔲 Funder	Shared§	🔲 Don't know
D.1.7	Interpreting the data*†	Study team	🔲 Funder	Shared§	🔲 Don't know
D.1.8	Supervising or coordinating the study	Study team	🔲 Funder	🔲 Shared§	🔲 Don't know
D.1.9	Deciding on the <u>dissemination plan</u> related to study results	Study team	E Funder	Shared§	Don't know
D.1.10	If the study is published, who bears final respon- sibility for and/or has ultimate authority over the following areas of the manuscript development?				
D.1.10a	Drafting all or parts of the manuscript(s)*+	Study team	🔲 Funder	Shared§	Don't know
D.1.10b	Revising the manuscript(s) for important intellectual content*†	Study team	🔲 Funder	Shared§	Don't know
D.1.10c	Giving final approval of the version to be published*†	Study team	Funder	Shared§	Don't know
D.1.10d	Deciding where the manuscript(s) will be submitted for publication ⁺	Study team	Funder	Shared§	Don't know
D.1.10e	Deciding the timing of the manuscript(s) submission for publication ⁺	Study team	🔲 Funder	Shared§	Don't know
D.1.10f	Deciding authorship	Study team	🔲 Funder	Shared§	Don't know
D.1.10g	Deciding authorship order ‡	Study team	Funder	□ Shared§	Don't know
D.1.10h	Acting as the study guarantor [‡]	Study team	Funder	Shared§	Don't know
D.1.10i	Providing administrative, technical or logistic support	Study team	Funder	Shared§	Don't know

* Based on International Committee of Medical Journal Editors (ICMJE), II.A.1. Byline authors, *Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication* (2008).¹This document describes the ICMJE's three criteria for authorship.

⁺ Based on ICMJE, II.D.2. Potential conflicts of interest related to project support, *Uniform requirements for manuscripts submitted to biomedical journals:* writing and editing for biomedical publication (2008).¹

‡ Based on World Association of Medical Editors (WAME), Policy statements: authorship.²

§ Responsibility and/or authority are shared by the study team and the funder.

Date the checklist section 2 was first completed (day/month/year)

<u>19/10/2018</u>

Date(s) the checklist section 2 was updated (day/month/year)

SECTION 3: PERSONAL FINANCIAL INFORMATION

This section is completed at the study's initiation and updated as necessary.

Date(s) the checklist section 3 was updated (day/month/year)

MODULE E:	FINANCIAL PROFILE		
ITEM	DESCRIPTOR	RESPONSE	
E.1.0	Does this study provide you with salary support?	Yes No	
E.1.1	If you answered yes to item E.1.0, what percentage of your annual salary do you estimate will be obtained from the funder(s)?	<u>Not Ap</u> plicable	
E.2.0	Will you personally receive direct or indirect financial benefit for your role in thisstudy?	Yes 🗋 No 🛄 Don't know	
E.2.1	If you answered yes to item E.2.0, what is the amount?	\$ <u>712 incentive for publication</u>	
E.3.0	Will your department or institution receive or has it received	Yes, it does now	
	financial benefit (e.g., direct funding, gifts, general use or discretionary funds or any other payment above your	Yes, it has in the past	
	institution's standard administrative overhead rate) from the study funder(s)? (check all that apply)	Yes, it will in the future	
		No	
		Don't know	
E.3.1	If you answered yes to item E.3.0, please specify the financial benefit:	Don't know	
E.4.0	Does this study involve the commercialization of intellectual property (e.g., through patents, copyrights or royalties from such rights)?	🗋 Yes 📕 No 🔲 Don't know	
E.4.1	If you answered yes to item E.4.0, who receives the financial benefit from this commercialization?	Not Applicable	
E.4.2	If you answered yes to item E.4.0, how is the intellectual property commer- cialized (e.g., through patents, copyrights or royalties from such rights)?	Not Applicable	
E.5.0	Do you have any financial interests related to competitor(s) of the funder(s) of your study?	Yes No	
E.5.1	If you answered yes to item E.5.0, please specify:	Not Applicable	
E.6.0	Do you currently have or expect to have any financial interests related to the study funder(s)?	🗋 Yes 📕 No 🔲 Don't know	
E.6.1	If you answered yes to item E.6.0, please specify:	Not Applicable	
E.7.0	Do any of your immediate family members (spouse or spouse equivalent, dependent child) currently have or expect to have any financial interests related to the study funder(s)?	🗋 Yes 📕 No 🔲 Don't know	
E.7.1	If you answered yes to item E.7.0, please specify:	Not Applicable	
Date the chec	klist section 3 was first completed (day/month/year)	19/10/2018	

SECTION 4: AUTHORSHIP INFORMATION

This section is completed when a manuscript is being submitted for publication.

MODULE	F: AUTHORSHIP PROFILE	
ITEM	DESCRIPTOR	RESPONSE
F.1.0	Is there a manuscript submitted for publication?	🗋 Yes 📕 No
F.1.1	If you answered yes to item F.1.0, what is the title of the manuscript?	Not Applicable
F.2.0	Are you an author on this manuscript?	Yes 🔲 No
F.2.1	To which aspects of the study and the manuscript development did you make a substantial contribution?	
F.2.1a	Obtaining funding‡	Yes 🔲 No
F.2.1b	Conceptualizing and designing the study*	Yes 🔲 No
F.2.1c	Providing study materials and/or recruiting participants‡	🗋 Yes 📕 No
F.2.1d	Collecting or assembling data*	Yes 🔲 No
F.2.1e	Analyzing and interpreting data*	Yes 🔲 No
F.2.1f	Providing statistical expertise [‡]	Yes 🔲 No
F.2.1g	Supervising or coordinating the study [‡]	Yes 🔲 No
F.2.1h	Drafting all or part of the manuscript*	Yes 🔲 No
F.2.1i	Revising the manuscript for important intellectual content*	Yes 🔲 No
F.2.1j	Giving final approval of the version to be published*	Yes 🔲 No
F.2.1k	Providing administrative, technical or logistic support‡	Yes No
F.2.2	Are you the study <u>guarantor</u> ? [†]	Yes 🔲 No
F.3.0	Are you aware of the involvement of a <u>guest</u> or <u>ghost author</u> ?†	Yes No

* Based on ICMJE, II.A.1. Byline authors, Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication (2008).¹ This document describes the ICMJE's three criteria for authorship.

⁺ Based on WAME, Policy statements: authorship.²

[‡] Derived from the JAMA Authorship responsibility, financial disclosure, acknowledgment, and copyright transfer/publishing agreement;³ some are also mentioned in ICMJE¹ and WAME²

19/10/2018

Date the checklist section 4 was first completed (day/month/year) Date(s) the checklist section 3 was updated (day/month/year)

Table 1: Financial Conflicts of Interest Checklist 2010

(Underlined terms are defined in the Glossary)

The Financial Conflicts of Interest Checklist 2010 was designed to be completed by each investigator in the context of a specific clinical research study.

As awareness of financial conflict of interest issues grows, we see the checklist being completed by other study team members, such as study coordinators, research assistants and study nurses. This checklist contains four sections: administrative information, study information, personal financial information, and authorship information. The investigator is expected to complete the checklist prospectively as the clinical research moves through its various stages. Sections 1, 2 and 3 are first filled out at the study's initiation, updated as required, and completed when the study manuscript is submitted for publication; section 4 is also completed at this time.

SECTION 1: ADMINISTRATIVE INFORMATION

This section is completed at the study's initiation and updated as necessary.

ITEM	DESCRIPTOR	RESPONSE
A.1.0		nt on lifestyle and cardio-metabolic profile in m natic review and planned meta-analysis.
A.1.1	Study name	
A.1.2	Singlesite or 🔲 multi-site	
A.1.3	Countries in which the data will be collected	Chile
A.1.4	Is this a <u>clinical trial</u> ?	🔲 Yes 📕 No
A.1.4a	If you answered yes to item A.1.4:	
	Is the study registered in a primary <u>clinical trial registry</u> international standards developed by the World Health endorsed by the International Committee of Medical Jo	Organization and
	A list of approved registries can be found at <u>http://www.who.int/ictrp/network/primary/en/index.htn</u>	<u>I</u>
A.1.4b	What is the primary registry name and the registration	number? <u>CRD42017069924</u>
A.1.5	Name of the institution from which the study will be coor	linated Universidad de Atacama
A.1.6	Is any part of the study to be conducted by a <u>contract res</u>	earch organization? 🔲 Yes 📕 No
A.2.0	Investigator	
A.2.1	Name of the overall study official	José Fernández Cao
A.2.2	Name of the investigator completing the checklist	Carlos Doepking Mella
A.2.3	What is your role in this research study? (check all that ap	ply)
A.2.3a	Principal investigator for the entire study	🔲 Yes 📕 No
A.2.3b	Principal investigator for a site or region	🗋 Yes 📕 No
А.2.3с	Co-investigator for the study	Yes 🔲 No
A.2.3d	Paid consultant for the study	🔲 Yes 🗾 No
А.2.3е	Member of steering committee	🔲 Yes 📕 No
A.2.3f	Participant recruiter	🔲 Yes 🚺 No
A.2.3g	Other (please specify)	
Date the c	hecklist section 1 was first completed (day/month/year)	_19/09/2018

Date(s) the checklist section 1 was updated (day/month/year)

SECTION 2: STUDY INFORMATION

This section is completed at the study's initiation and updated as necessary.

MODULE B: FUNDER PROFILE				
ITEM	DESCRIPTOR	RESPONSE		
B.1.0	Is this studyfunded?	🗋 Yes 📕 No 🔲 Don't know		
B.1.1	If you answered yes to item B.1.0, identify the type of funding support:			
	🔲 Financial 🔲 Equipment 🔲 Test kit 🔲 Drug 🔲 Device			
B.1.2	Other (please specify:) List the <u>funder(s)</u>	Not Applicable		
B.1.3	To which categories do/does the funder(s) belong? (check all that apply):			
В.1.3а	Industry (e.g., pharmaceutical company, test or medical device company, biotech company)	🗋 Yes 📕 No		
B.1.3b	Government funding agency (e.g., National Institutes of Health, Canadian Institutes of Health Research, Medical Research Council)	Yes No		
В.1.3с	National or regional government body (e.g., National Health Service, Ministry of Health, Department of Defense)	🗋 Yes 📕 No		
B.1.3d	Charitable foundation (e.g., American Heart Association, The Bill & Melinda Gates Foundation, Wellcome Trust)	🗋 Yes 📕 No		
В.1.3е	Other(s) (please specify:)	🗋 Yes 🔳 No		

MODULE	C: CONTRACT PROFILE	
ITEM	DESCRIPTOR	RESPONSE
C.1.0	Is there a <u>contract</u> with the funder(s)? (If you answered no or don't know, skip to module D) If you answered yes to item C.1.0, does your contract:	🗋 Yes 📕 No 📮 Don't know
C.1.1	include someone signing on behalf of your institution?	🗋 Yes 🔲 No
C.1.2	require you to obtain additional funds for this research study from other sources?	🗋 Yes 🔲 No
C.1.3	contain a clause that prohibits you from disclosing certain aspects abou the study without the permission of the funder?	t 🗋 Yes 🗋 No
C.1.4	specify the maximum allowable time for pre-publication review by the funder?	Yes No
С.1.4а	If you answered yes to item C.1.4, what is that time?	Not App <u>licable_</u> days

	: STUDY TEAM AND FUNDER RELATIONSHIP	PROFILE			
ITEM	DESCRIPTOR	RESPONSE			
D.1.0	Who bears final responsibility for and/or has u authority over the following areas of the stuc				
D.1.1	Conceptualizing and designing the study *+	Study team	🔲 Funder	Shared§	Don't know
D.1.2	Approving the final design [†]	Study team	🔲 Funder	Shared§	🔲 Don't know
D.1.3	Approving the final data analysis plan	Study team	🔲 Funder	Shared§	Don't know
D.1.4	Recruiting participants	Study team	🔲 Funder	Shared§	🔲 Don't know
D.1.5	Collecting or assembling data*+	Study team	🔲 Funder	Shared§	Don't know
D.1.6	Analyzing the data*†	Study team	🔲 Funder	Shared§	Don't know
D.1.7	Interpreting the data*†	Study team	🔲 Funder	Shared§	🔲 Don't know
D.1.8	Supervising or coordinating the study	Study team	🔲 Funder	Shared§	🗋 Don't know
D.1.9	Deciding on the <u>dissemination plan</u> related to study results	Study team	🔲 Funder	Shared§	Don't know
D.1.10	If the study is published, who bears final respon- sibility for and/or has ultimate authority over the following areas of the manuscript development?				
D.1.10a	Drafting all or parts of the manuscript(s)*+	Study team	🔲 Funder	Shared§	Don't know
D.1.10b	Revising the manuscript(s) for important intellectual content*†	Study team	🔲 Funder	Shared§	Don't know
D.1.10c	Giving final approval of the version to be published*†	Study team	🔲 Funder	Shared§	Don't know
D.1.10d	Deciding where the manuscript(s) will be submitted for publication [†]	Study team	🔲 Funder	Shared§	Don't know
D.1.10e	Deciding the timing of the manuscript(s) submission for publication ⁺	Study team	E Funder	Shared§	Don't know
D.1.10f	Deciding authorship	Study team	🔲 Funder	Shared§	Don't know
D.1.10g	Deciding authorship order ‡	Study team	🔲 Funder	Shared§	Don't know
D.1.10h	Acting as the study guarantor‡	Study team	Funder	Shared§	Don't know
D.1.10i	Providing administrative, technical or logistic support	Study team	Funder	Shared§	Don't know

* Based on International Committee of Medical Journal Editors (ICMJE), II.A.1. Byline authors, *Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication* (2008).¹This document describes the ICMJE's three criteria for authorship.

⁺ Based on ICMJE, II.D.2. Potential conflicts of interest related to project support, *Uniform requirements for manuscripts submitted to biomedical journals:* writing and editing for biomedical publication (2008).¹

[‡] Based on World Association of Medical Editors (WAME), Policy statements: authorship.²

§ Responsibility and/or authority are shared by the study team and the funder.

Date the checklist section 2 was first completed (day/month/year)

<u>19/09/2018</u>

Date(s) the checklist section 2 was updated (day/month/year)

SECTION 3: PERSONAL FINANCIAL INFORMATION

This section is completed at the study's initiation and updated as necessary.

MODULE E:	FINANCIAL PROFILE			
ITEM	DESCRIPTOR	RESPONSE		
E.1.0	Does this study provide you with salary support?	Yes No		
E.1.1	If you answered yes to item E.1.0, what percentage of your annual salary do you estimate will be obtained from the funder(s)?	<u>Not Ap</u> plicable		
E.2.0	Will you personally receive direct or indirect financial benefit for your role in thisstudy?	Yes 🗋 No 🛄 Don't know		
E.2.1	If you answered yes to item E.2.0, what is the amount?	\$ 712 by publication		
E.3.0	Will your department or institution receive or has it received financial benefit (e.g., direct funding, gifts, general use or discretionary funds or any other payment above your institution's standard administrative overhead rate) from the study funder(s)? (check all that apply)	Yes, it does now		
		Yes, it has in the past		
		Yes, it will in the future		
		No		
		Don't know		
E.3.1	If you answered yes to item E.3.0, please specify the financial benefit:	Not Applicable		
E.4.0	Does this study involve the commercialization of intellectual property (e.g., through patents, copyrights or royalties from such rights)?	🗋 Yes 📕 No 🔲 Don't know		
E.4.1	If you answered yes to item E.4.0, who receives the financial benefit from this commercialization?	Not Applicable		
E.4.2	If you answered yes to item E.4.0, how is the intellectual property commer- cialized (e.g., through patents, copyrights or royalties from such rights)?	Not Applicable		
E.5.0	Do you have any <u>financial interests</u> related to competitor(s) of the funder(s) of your study?	Yes No		
E.5.1	If you answered yes to item E.5.0, please specify:	Not Applicable		
E.6.0	Do you currently have or expect to have any financial interests related to the studyfunder(s)?	🗋 Yes 📕 No 🔲 Don't know		
E.6.1	If you answered yes to item E.6.0, please specify:	Not Applicable		
E.7.0	Do any of your immediate family members (spouse or spouse equivalent, dependent child) currently have or expect to have any financial interests related to the study funder(s)?	🗋 Yes 📕 No 🔲 Don't know		
E.7.1	If you answered yes to item E.7.0, please specify:	Not Applicable		
Date the checklist section 3 was first completed (day/month/year)		19/09/2018		

Date(s) the checklist section 3 was updated (day/month/year)

SECTION 4: AUTHORSHIP INFORMATION

This section is completed when a manuscript is being submitted for publication.

MODULE F: AUTHORSHIP PROFILE					
ITEM	DESCRIPTOR	RESPONSE			
F.1.0	Is there a manuscript submitted for publication?	🔲 Yes 📕 No			
F.1.1	If you answered yes to item F.1.0, what is the title of the manuscript?	Not Applicable			
F.2.0	Are you an author on this manuscript?	Yes 🔲 No			
F.2.1	To which aspects of the study and the manuscript development did you make a substantial contribution?				
F.2.1a	Obtaining funding‡	Yes No			
F.2.1b	Conceptualizing and designing the study*	Yes 🗋 No			
F.2.1c	Providing study materials and/or recruiting participants [‡]	Yes No			
F.2.1d	Collecting or assembling data*	Yes 🔲 No			
F.2.1e	Analyzing and interpreting data*	Yes 🔲 No			
F.2.1f	Providing statistical expertise [‡]	🗋 Yes 📕 No			
F.2.1g	Supervising or coordinating the study‡	🗋 Yes 📕 No			
F.2.1h	Drafting all or part of the manuscript*	🗋 Yes 📕 No			
F.2.1i	Revising the manuscript for important intellectual content*	Yes 🗋 No			
F.2.1j	Giving final approval of the version to be published*	Yes 🔲 No			
F.2.1k	Providing administrative, technical or logistic support [‡]	🗋 Yes 📕 No			
F.2.2	Are you the study <u>guarantor</u> ? ⁺	Yes No			
F.3.0	Are you aware of the involvement of a guest or ghost author?†	Yes No			

* Based on ICMJE, II.A.1. Byline authors, Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication (2008).¹ This document describes the ICMJE's three criteria for authorship.

⁺ Based on WAME, Policy statements: authorship.²

[‡] Derived from the JAMA Authorship responsibility, financial disclosure, acknowledgment, and copyright transfer/publishing agreement;³ some are also mentioned in ICMJE¹ and WAME²

19/09/2018

Date the checklist section 4 was first completed (day/month/year) Date(s) the checklist section 3 was updated (day/month/year)